A Phase III trial of AXS-07 for the acute treatment of migraine

Trial Profile

A Phase III trial of AXS-07 for the acute treatment of migraine

Planning
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Meloxicam/rizatriptan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Axsome Therapeutics
  • Most Recent Events

    • 30 Nov 2017 New trial record
    • 28 Nov 2017 According to an Axsome Therapeutics media release, based on theUS FDA feedback the company plans to initiate this trial in 2018. Data from this trial will utilized for the approval of AXS-07 for the treatment of migraine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top